Neurological Advisory Committee recommends migraine medications receive high priority funding
Press release Migraine Foundation Aotearoa New Zealand welcomes Pharmac’s Neurological Advisory Committee recommendation that migraine-specific medications should be funded with a high priority. At its September meeting, the Committee reviewed the evidence for funding galcanezumab (Emgality), erenumab (Aimovig) and atogepant (Aquipta) for chronic and episodic migraine. All three medications were developed specifically to prevent migraine, […]
Migraine while flying and travelling
As the summer holidays approach, many people are gearing up to jump on a plane to spend time with family and friends or to have an escape or adventure, either here in Aotearoa New Zealand or overseas. Flying, and even travel in general, can create an environment where migraine attacks are more likely to occur […]
Emgality supply issue – NZ shouldn’t be affected
This week we received emails from the Australian and New Zealand Headache Society and Migraine and Headache Australia that galcanezumab (Emgality) was out of stock until 1 April 2024 due to a global supply shortage. Greatly perturbed, we contacted CDC Pharmaceuticals who have the sole supply of Emgality in NZ. They hadn’t received any notification […]
Emgality price increase? Thankfully not
We’ve heard some people taking Emgality have been told by their pharmacists that the price of Emgality is going to increase next year, by as much as double by February 2024. This has been predominantly in the Bay of Plenty and Auckland area. We contacted the pharmaceutical supplier CDC Pharmaceuticals (CDC) about this. CDC is […]
Migraine and menopause
Many women with migraine have been told that migraine will improve after menopause. Should we be hanging out until our periods stop? Menopause is the time in a woman’s life when periods have totally ceased and the ovaries no longer produce eggs. Officially, it’s when you’ve gone for 12 months without a period. Perimenopause is […]
Migraine in transgender people
What can we learn from the experience of migraine in transgender people and what can be done for transgender people with migraine? Most research on migraine doesn’t distinguish between sex and gender. Sex is a biological construct, technically categorised as male, female and intersex (but more often as a male/female binary) and is based on […]
Migraine in men
Migraine is more common in women than men – but this can mean that men with migraine get overlooked. The reason migraine is more common in women is mostly attributed to hormonal differences and changes in women, from puberty to menopause. Women have higher and fluctuating levels of the sex hormone estrogen during child-bearing years […]
Highlights from International Headache Congress 2023
The International Headache Society (IHS) is the leading international headache charity, which exists to promote awareness and knowledge about headache worldwide, through science, education and advocacy. They publish the International Classification of Headache Disorders, which underpins the diagnosis of migraine and other headache disorders. Their official journal, Cephalalgia, publishes ground-breaking research on all aspects of headache. And every two […]
WINZ contributes to Emgality costs
There aren’t many people in New Zealand who are on a benefit because of migraine, despite migraine being a common and disabling disease, that can seriously impair people’s ability to work. But if you are, and you want to try the new migraine medication Emgality, but can’t afford it, here’s a story of hope. Cheryl (not her […]
What I learnt from a headache specialist
The New Zealand Pain Society is an organisation that promotes education and training in all areas of pain management and research. It regularly organises webinars for members, and on 10 August 2023 hosted Migraine Foundation Aotearoa New Zealand (MFANZ) to present an “Update on migraine and its management and survey insights on living with migraine in Aotearoa […]
